Esta página web usa cookies. ¿Acepta usted el uso de cookies externos? No Saber más x
Encuesta sobre la acondroplasia
Hemos diseñado un cuestionario con el objetivo de conocer la población afectada o cercana a la acondroplasia.
El cuestionario es opcional y anónimo. Los datos obtenidos serán usados para cálculos estadísticos y para poder tener una mejor percepción sobre la historia natural de la acondroplasia.
Por favor, considere e intente responder. Si usted desea responder a las preguntas más tarde, puede presionar el botón en la parte superior "Inscribirse en BA"

How does gait differ in children with achondroplasia?

2021-03-12Research
What is still to be understood on how gait in children with achondroplasia is altered compared to average height children. 

What is still to be known about achondroplasia

2021-03-12Research
A recently published article by Julie Hoover-Fong et al.1 seeks to synthesize the current knowledge base about the nature, incidence, chronology, and the interrelationships of achondroplasia-related comorbidities across the lifespan.

New potential treatment for achondroplasia by the Tsumaki lab & Astellas Pharma Inc.

2020-12-27Research
The Tsumaki lab, at the Center for iPS Cell Research and Application (CiRA), Kyoto University, is leading new research for achondroplasia with ASP5878, an FGFR inhibitor, using iPS cells. This is a study in collaboration with Astellas Pharma.

First children with achondroplasia receive Recifercept

2020-12-16Research
Pfizer released a Press Statement of the first children with achondroplasia receiving Recifercept, initiating the Phase 2 clinical trial

Vosoritide phase 3 clinical trial data have been published

2020-09-30Research
Results from the phase 3 clinical trial for vosoritide, that involved children with achondroplasia with ages between 5 to 18 years have been published.
Para ver esta página web usted necesita de Internet Explorer 8 (o una versión más reciente)
u otro browser.


Muchas gracias.